The MO HealthNet Division (MHD) will begin to review requests for Synagis (palivizumab) effective October 30, 2023.
Due to current supply constraints for the new RSV prophylaxis agent Beyfortus (nirsevimab), MHD will allow up to two doses of Synagis for November and December 2023. Participants who meet the clinical edit requirements, including age restrictions, may receive approval for up to two doses to start the 2023 - 2024 RSV season, depending on the requested date for the initial prior authorization and the current availability of Beyfortus.
MHD recommends pharmacies coordinate with providers to ensure a scheduled appointment exists with their patient to administer Synagis before sending doses to reduce abandoned medication. MHD will evaluate claims to ensure there is no excessive waste.
Providers with questions may call MO HealthNet at 800-392-8030.